Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem Cell Source, and Alemtuzumab Regimen
| Autor: | Marsh, Rebecca A., Rao, Marepalli B., Gefen, Aharon, Bellman, Denise, Mehta, Parinda A., Khandelwal, Pooja, Chandra, Sharat, Jodele, Sonata, Myers, Kasiani C., Grimley, Michael, Dandoy, Christopher, El-Bietar, Javier, Kumar, Ashish R., Leemhuis, Tom, Zhang, Kejian, Bleesing, Jack J., Jordan, Michael B., Filipovich, Alexandra H., Davies, Stella M. |
|---|---|
| Zdroj: | In Biology of Blood and Marrow Transplantation August 2015 21(8):1460-1470 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect